Transmission of fluoroquinolones resistance among multidrug-resistant tuberculosis in Shanghai, China: a retrospective population-based genomic epidemiology study

被引:6
|
作者
Li, Minjuan [1 ]
Zhang, Yangyi [2 ,3 ,4 ,5 ]
Wu, Zheyuan [2 ,3 ]
Jiang, Yuan [2 ,3 ]
Sun, Ruoyao [1 ]
Yang, Jinghui [6 ]
Li, Jing [2 ,3 ]
Lin, Honghua [1 ]
Zhang, Rui [1 ]
Jiang, Qi [7 ]
Wang, Lili [2 ,3 ]
Wu, Xiaocui [6 ]
Yu, Fangyou [6 ]
Yuan, Jianhui [8 ]
Yang, Chongguang [1 ,8 ]
Shen, Xin [2 ,3 ]
机构
[1] Sun Yat Sen Univ, Sch Publ Hlth Shenzhen, Shenzhen Campus, Shenzhen, Guangdong, Peoples R China
[2] Shanghai Municipal Ctr Dis Control & Prevent, Div TB & HIV AIDS Prevent, 1380 Zhongshan West Rd, Shanghai 200336, Peoples R China
[3] Shanghai Inst Prevent Med, Shanghai, Peoples R China
[4] Fudan Univ, Sch Publ Hlth, Dept Epidemiol, Shanghai, Peoples R China
[5] Fudan Univ, Key Lab Publ Hlth Safety, Shanghai, Peoples R China
[6] Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Clin Lab, Shanghai, Peoples R China
[7] Wuhan Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Wuhan, Peoples R China
[8] Nanshan Dist Ctr Dis Control & Prevent, Shenzhen, Peoples R China
关键词
Multidrug-resistant tuberculosis; fluoroquinolones resistance; whole-genome sequencing; drug resistance transmission; China; MYCOBACTERIUM-TUBERCULOSIS; DRUG-RESISTANT; PREVALENCE;
D O I
10.1080/22221751.2024.2302837
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Fluoroquinolones (FQ) are essential for the treatment of multidrug-resistant tuberculosis (MDR-TB). The FQ resistance (FQ-R) rate in MDR-TB in China and its risk factors remain poorly understood. We conducted a retrospective, population-based genomic epidemiology study of MDR-TB patients in Shanghai, China, from 2009 to 2018. A genomic cluster was defined as strains with genetic distances <= 12 single nucleotide polymorphisms. The transmitted FQ-R was defined as the same FQ resistance-conferring mutations shared by >= 2 strains in a genomic cluster. We used multivariable logistic regression analysis to identify the risk factors for drug resistance. Among the total 850 MDR-TB patients included in the study, 72.8% (619/850) were male, the median age was 39 (interquartile range 28, 55) years, 52.7% (448/850) were migrants, and 34.5% (293/850) were previously treated patients. Most of the MDR-TB strains belong to the Beijing lineage (91.7%, 779/850). Overall, the genotypic resistance rate of FQ was 34.7% (295/850), and 47.1% (139/295) FQ-R patients were in genomic clusters, of which 98 (33.2%, 98/295) were presumed as transmitted FQ-R. Patients with treatment-naive (aOR = 1.84; 95% CI: 1.09, 3.16), diagnosed in a district-level hospital (aOR = 2.69; 95% CI: 1.56, 4.75), and streptomycin resistance (aOR = 3.69; 95% CI: 1.65, 9.42) were significantly associated with the transmission of FQ-R. In summary, the prevalence of FQ-R among MDR-TB patients was high in Shanghai, and at least one-third were transmitted. Enforced interventions including surveillance of FQ drug susceptibility testing and screening among MDR-TB before initiation of treatment were urgently needed.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Citywide Transmission of Multidrug-resistant Tuberculosis Under China's Rapid Urbanization: A Retrospective Population-based Genomic Spatial Epidemiological Study
    Jiang, Qi
    Liu, Qingyun
    Ji, Lecai
    Li, Jinli
    Zeng, Yaling
    Meng, Liangguang
    Luo, Geyang
    Yang, Chongguang
    Takiff, Howard E.
    Yang, Zheng
    Tan, Weiguo
    Yu, Weiye
    Gao, Qian
    CLINICAL INFECTIOUS DISEASES, 2020, 71 (01) : 142 - 151
  • [2] Transmission of multidrug-resistant tuberculosis in Shimen community in Shanghai, China: a molecular epidemiology study
    Han, Zhiying
    Li, Jing
    Sun, Guomei
    Gu, Kaikan
    Zhang, Yangyi
    Yao, Hui
    Jiang, Yuan
    BMC INFECTIOUS DISEASES, 2021, 21 (01)
  • [3] Transmission of multidrug-resistant tuberculosis in Shimen community in Shanghai, China: a molecular epidemiology study
    Zhiying Han
    Jing Li
    Guomei Sun
    Kaikan Gu
    Yangyi Zhang
    Hui Yao
    Yuan Jiang
    BMC Infectious Diseases, 21
  • [4] Impact of financial support on treatment outcomes of multidrug-resistant tuberculosis: A population-based, retrospective cohort study in Shanghai, China
    Chen, Yong
    Shen, Xin
    Zhang, Yi
    Wu, Zheyuan
    Xu, Biao
    Chen, Jing
    Sha, Wei
    Liu, Xiaoxia
    Ning, Chenxi
    JOURNAL OF CLINICAL TUBERCULOSIS AND OTHER MYCOBACTERIAL DISEASES, 2024, 37
  • [5] Transmission of multidrug-resistant tuberculosis in Beijing, China: An epidemiological and genomic analysis
    Yin, Jinfeng
    Zhang, Hongwei
    Gao, Zhidong
    Jiang, Hui
    Qin, Liyi
    Zhu, Chendi
    Gao, Qian
    He, Xiaoxin
    Li, Weimin
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [6] Multidrug-resistant tuberculosis clusters and transmission in Taiwan: a population-based cohort study
    Liu, Kuang-Hung
    Xiao, Yu-Xin
    Jou, Ruwen
    FRONTIERS IN MICROBIOLOGY, 2024, 15
  • [7] Impact of different tuberculosis history at the onset of future multidrug-resistant tuberculosis: A large, retrospective, population-based cohort study
    Cheng, Qinglin
    Xie, Li
    Wang, Le
    Lu, Min
    Li, Qingchun
    Wu, Yifei
    Huang, Yinyan
    Jia, Qingjun
    Zhao, Gang
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2021, 24 : 158 - 168
  • [8] Characteristics of multidrug-resistant Mycobacterium tuberculosis in Taiwan: A population-based study
    Chang, Chia-Wei
    Wu, Mei-Hua
    Chuang, Pei-Chun
    Jou, Ruwen
    INFECTION GENETICS AND EVOLUTION, 2011, 11 (03) : 633 - 639
  • [9] Population-based investigation of fluoroquinolones resistant tuberculosis in rural eastern China
    Hu, Yi
    Mathema, Barun
    Wang, Weibing
    Kreiswirth, Barry
    Jiang, Weili
    Xu, Biao
    TUBERCULOSIS, 2011, 91 (03) : 238 - 243
  • [10] Transmission of multidrug-resistant Mycobacterium tuberculosis in Wuhan, China A retrospective molecular epidemiological study
    Duan, Qionghong
    Zhang, Zhengbin
    Tian, Dan
    Zhou, Meilan
    Hu, Yanjie
    Wu, Jun
    Wang, Tiantian
    Li, Yuehua
    Chen, Jun
    MEDICINE, 2022, 101 (04) : E28751